Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols
Sinusoidal obstructive syndrome (SOS), previously known as hepatic veno-occlusive disease (VOD), has been recognized as a complex and life-threatening complication following hematopoietic stem cell transplantation (HSCT). SOS is a complication that develops after injury to the micro-vasculature and endothelial cells of the liver. Damage to endothelial cells promotes increased expression of pro-inflammatory cytokines and adhesion molecules in the vascular endothelium, leading to sinusoidal narrowing and micro-vascular occlusion, altered liver cytoskeletal architecture, weakened intercellular junctions, and further liver dam...
Source: Biology of Blood and Marrow Transplantation - April 15, 2024 Category: Hematology Authors: Gabriel Salinas Cisneros, Christopher C Dvorak, Janel Long-Boyle, Sandhya Kharbanda, Kristin A Shimano, Alexis Melton, Julia Chu, Lena E Winestone, Jasmeen Dara, James N Huang, Michelle L Hermiston, Matt Zinter, Christine S Higham Source Type: research

Listeria monocytogenes infections in hematopoietic cell transplant recipients: clinical manifestations and risk factors: A multinational retrospective case control study of the Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Listeria spp. is a facultative intracellular bacillus that can infect humans following ingestion of contaminated food1. There are several species of Listeria, of which Listeria monocytogenes (LM) and (rarely) Listeria ivanovii can cause infection in humans2. Following gastrointestinal infection, Listeria can spread to the bloodstream and brain, and is one of the most common etiologies of central nervous system (CNS) infection in immunocompromised patients3. The most common manifestation of listeriosis in the immune-competent is mild gastroenteritis. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 15, 2024 Category: Hematology Authors: Dina Averbuch, Gloria Tridello, Lotus Wendel, Maija It älä-Remes, Ilana Oren, Michal Karas, Nicole Blijlevens, Yves Beguin, Annoek Broers, Elisabetta Calore, Chiara Cattaneo, Cecilia Isaksson, Christine Robin, Alain Gadisseur, Johan Maertens, Ann De Bec Source Type: research

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy
Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is not uncommon and remains a major therapeutic challenge. There is substantial variability across transplantation and cellular therapy programs in assessing and managing post CAR-T failures in RRMM. The American Society for Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines conducted an online cross-sectional survey between September 2023 and December 2023 to determine the myeloma, transplantation and cellular therapy physician...
Source: Biology of Blood and Marrow Transplantation - April 11, 2024 Category: Hematology Authors: Hamza Hashmi, Ambuj Kumar, Mohamed A. Kharfan-Dabaja, Pashna N. Munshi, Yoshihiro Inamoto, Zachariah M. DeFilipp, Bhagirathbhai Dholaria, Tania Jain, Miguel-Angel Perales, Paul A. Carpenter, Mehdi Hamadani, Binod Dhakal, Saad Z. Usmani Source Type: research

Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force
According to the Center for International Blood and Marrow Transplant Research (CIBMTR) 23,535 hematopoietic cell transplants (HCT) were performed in the United States in 2019.1 The number of HCT in the US is rising, having nearly doubled since the previous decade.1 While there has been a steady increase in the number of autologous HCTs, the number of allogeneic HCTs has also risen considerably. With a robust donor registry, the increasing use of haploidentical and mismatched unrelated donors, and improvement in transplant techniques and supportive care, the majority of patients who need an allogeneic HCT will find a suita...
Source: Biology of Blood and Marrow Transplantation - April 10, 2024 Category: Hematology Authors: Akshay Sharma, Agnieszka Czechowicz, Melissa Mavers, Nelson Chao, John DiPersio, Pavan Reddy, Miguel-Angel Perales, Melody Smith Source Type: research

INSPIRED Symposium Part 5: Expanding the Use of CAR T cells in Children and Young Adults
Chimeric antigen receptor (CAR) T cell therapies have shown remarkable efficacy in the treatment of relapsed/refractory (r/r) B cell malignancies, including in children and young adults with B cell acute lymphoblastic leukemia (ALL).1-7 However, the efficacy that CAR T cell therapies have shown in B cell malignancies has not yet translated to equivalent success in non-B cell hematologic malignancies, central nervous system (CNS) tumors, and non-CNS solid tumors. Emerging strategies to enhance CAR T cell efficacy and safety for other malignancies have begun to show promise in early-phase clinical trials. (Source: Biology of...
Source: Biology of Blood and Marrow Transplantation - April 6, 2024 Category: Hematology Authors: Aimee C. Talleur, Vanessa A. Fabrizio, Richard Aplenc, Stephan A. Grupp, Crystal Mackall, Robbie Majzner, Rosa Nguyen, Rayne Rouce, Amy Moskop, Kevin O. McNerney Source Type: research

The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities
Allogeneic hematopoietic cell transplantation (HCT) represents one of the major treatment modalities for both malignant and nonmalignant hematologic diseases. The majority of patients in need of HCT do not have an available human leukocyte antigen (HLA) matched related donor, thus the use of both HLA-matched and HLA-mismatched unrelated donors (URD) has continued to increase1,2. One of the major risks associated with URD HCT is graft-versus-host disease (GVHD)3,4, with many clinical trials directed towards preventing or treating this significant transplant complication. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 5, 2024 Category: Hematology Authors: Takuto Takahashi, Benjamin Watkins, Brandi Bratrude, Donna Neuberg, Kyle Hebert, Kayla Betz, Alison Yu, Sung W Choi, Jeffrey Davis, Christine Duncan, Roger Giller, Michael Grimley, Andrew C. Harris, David Jacobsohn, Nahal Lalefar, Nosha Farhadfar, Michael Source Type: research

Evaluation of Circulating Endothelial Cells (CECs) as direct marker of endothelial damage in allo-transplanted patients at high risk of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
Sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD) is a severe and potentially life-threatening complication occurring after chemotherapy, conjugated antibodies therapy, and allogenic hematopoietic cell transplantation (allo-HCT)1,2. Rarely, it can occur after high doses of radiotherapy3, liver transplantation4, or ingestion of toxic alkaloids (toxic injury)5. SOS/VOD with painful hepatomegaly, fluid retention with ascites, weight gain, and jaundice2. Severe forms of SOS/VOD can swiftly progress to multi-organ dysfunction (MOF) and are associated with a very high mortality rate (>80%). (Sourc...
Source: Biology of Blood and Marrow Transplantation - April 4, 2024 Category: Hematology Authors: M. Farina, M.C. Scaini, A. Facchinetti, A. Leoni, S. Bernardi, C. Catoni, E. Morello, V. Radici, Filippo Frioni, E. Campodonico, G. Traverso, G. Cavallaro, A. Olivieri, P. Galieni, N. Di Renzo, F. Patriarca, P. Carluccio, C. Skert, E. Maffini, S. Pellizze Source Type: research

Trajectory of Sleep, Depression, and Quality of Life in Pediatric HSCT Recipients
Adult hematopoietic stem cell transplant (HSCT) recipients and adult caregivers of pediatric HSCT recipients have poor sleep, due in part to nocturia, staff cares, and noise [1 –5]. In these patients, the effects of prolonged sleep disruption during hospitalization have been shown to persist for months after discharge, negatively affecting sleep hygiene as well as quality of life [6–8]. Adult HSCT patients have been shown to have sleep disturbances up to 1-year post-tr ansplant, and these disturbances occur concurrently with depression and anxiety [9,10]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 3, 2024 Category: Hematology Authors: YunZu Michele Wang, John F. Huber, Laura Flesch, Kathy Demmel, Adam Lane, Dean W. Beebe, Lori Crosby, John Hogenesch, David F. Smith, Stella Davies, Christopher E. Dandoy Tags: Brief Article Source Type: research

Trajectory of Sleep, Depression and Quality of Life in Pediatric HSCT Recipients
Adult hematopoietic stem cell transplant (HSCT) recipients and adult caregivers of pediatric HSCT recipients have poor sleep, due in part to nocturia, staff cares, and noise.1 –5 In these patients, the effects of prolonged sleep disruption during hospitalization have been shown to persist for months after discharge, negatively affecting sleep hygiene as well as quality of life.6–8 Adult HSCT patients have been shown to have sleep disturbances up to one-year post-trans plant, and these disturbances occur concurrently with depression and anxiety. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 3, 2024 Category: Hematology Authors: YunZu Michele Wang, John F. Huber, Laura Flesch, Kathy Demmel, Adam Lane, Dean W. Beebe, Lori Crosby, John Hogenesch, David F. Smith, Stella Davies, Christopher E. Dandoy Source Type: research

A More MAGICal Alogrithm in Acute GVHD
Acute Graft-versus-Host Disease (aGVHD) is an unpredictable and potentially life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT).1 Inroads have been made, identifying two biologically relevant markers of aGVHD: suppression of tumorigenicity 2 (ST2) and Regenerating islet-derived 3-alpha (Reg-3 α).2,3 ST2 is the soluble receptor of interleukin-33 that is released when gastrointestinal crypt is damaged.4 Reg-3α is a peptide with regenerative property released from damaged intestinal crypt in the event of GVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Authors: Sanghee Hong, Stefanie Sarantopoulos Tags: The Bottom Line Source Type: research

Building a Transplant Center: From the Karolinska to Kathmandu
In the Icelandic language, the word von means hope, an uplifted spirit, persistence and enduring resilience. From the founding of bone marrow transplantation (BMT) by Don Thomas and other pioneers, this Nordic term has come to symbolize the journey of both transplant recipients and their physicians. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Authors: Olle Ringden, Damiano Rondelli Tags: Reflections Source Type: research

Picture Perfect Predictive Model: Does it Exist?
Editorial (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Authors: Chiranjeevi Sainatham, Tania Jain Tags: The Bottom Line Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Source Type: research

Officers and Directors of ASTCT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Source Type: research